Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer's disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 2, 2017, Pages E200-E208

  Habchi, Johnny ^a   Chia, Sean ^a   Limbocker, Ryan ^a   Mannini, Benedetta ^a   Ahn, Minkoo ^a   Perni, Michele ^a   Hansson, Oskar ^b,c   Arosio, Paolo ^a   Kumita, Janet R ^a   Challa, Pavan Kumar ^a   Cohen, Samuel I A ^a   Linse, Sara ^d   Dobson, Christopher M ^a   Knowles, Tuomas P J ^a   Vendruscolo, Michele ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Alzheimer's disease; Amyloid peptide; Drug discovery; Protein aggregation; Protein misfolding

Indexed keywords

3,5 DI TERT BUTYL 4' CHALCONECARBOXYLIC ACID; 4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1,3 DIOXOLAN 2 YL]BENZOIC ACID; ADAPALENE; AMYLOID BETA PROTEIN[1-42]; BEXAROTENE; BMS 195614; BMS 493; BMS 753; CD 1530; LIGAND; MM 11253; RETINOID A RECEPTOR; RETINOID X RECEPTOR; TAMIBAROTENE; UNCLASSIFIED DRUG; VITAMIN RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; CAENORHABDITIS ELEGANS; CEREBROSPINAL FLUID; CHEMICAL REACTION KINETICS; CONFERENCE PAPER; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN MISFOLDING; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; HUMAN; METABOLISM; MOLECULAR LIBRARY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CAENORHABDITIS ELEGANS; CEREBROSPINAL FLUID; DRUG DISCOVERY; HUMANS; PEPTIDE FRAGMENTS; SMALL MOLECULE LIBRARIES;

EID: 85009348250     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1615613114     Document Type: Article

References (39)

1. Alzheimer's Association (2012) 2012 Alzheimer's disease facts and figures. Alzheimers Dement 8(2):131-168.
2. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297(5580):353-356.
3. Selkoe DJ (2003) Folding proteins in fatal ways. Nature 426(6968):900-904.
4. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8(2):101-112.
5. Dobson CM (2003) Protein folding and misfolding. Nature 426(6968):884-890.
6. Knowles TP, Vendruscolo M, Dobson CM (2014) The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol 15(6):384-396.
7. Holtzman DM, Morris JC, Goate AM (2011) Alzheimer's disease: The challenge of the second century. Sci Transl Med 3(77):77sr1.
8. Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120(4):545-555.
9. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 10(9):698-712.
10. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148(6):1204-1222.
11. Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8(6):595-608.
12. Bateman RJ, et al.; Dominantly Inherited Alzheimer Network (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367(9): 795-804.
13. Buchhave P, et al. (2012) Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69(1):98-106.
14. Bieschke J (2013) Natural compounds may open new routes to treatment of amyloid diseases. Neurotherapeutics 10(3):429-439.
15. Chen J, Armstrong AH, Koehler AN, Hecht MH (2010) Small molecule microarrays enable the discovery of compounds that bind the Alzheimer's Aβ peptide and reduce its cytotoxicity. J Am Chem Soc 132(47):17015-17022.
16. Lansbury PT, Lashuel HA (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443(7113):774-779.
17. Necula M, Kayed R, Milton S, Glabe CG (2007) Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 282(14):10311-10324.
18. Cummings JL, Morstorf T, Zhong K (2014) Alzheimer's disease drug-development pipeline: Few candidates, frequent failures. Alzheimers Res Ther 6(4):37.
19. Karran E, Hardy J (2014) A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol 76(2):185-205.
20. De Strooper B, Karran E (2016) The cellular phase of alzheimer's disease. Cell 164(4): 603-615.
21. Arosio P, Vendruscolo M, Dobson CM, Knowles TP (2014) Chemical kinetics for drug discovery to combat protein aggregation diseases. Trends Pharmacol Sci 35(3):127-135.
22. Habchi J, et al. (2016) An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer's disease. Sci Adv 2(2):e1501244.
23. Cohen SI, et al. (2015) A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers. Nat Struct Mol Biol 22(3):207-213.
24. Cohen SI, et al. (2013) Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. Proc Natl Acad Sci USA 110(24):9758-9763.
25. Cohen SI, Vendruscolo M, Dobson CM, Knowles TP (2012) From macroscopic measurements to microscopic mechanisms of protein aggregation. J Mol Biol 421(2-3): 160-171.
26. Boehm MF, et al. (1995) Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 38(16):3146-3155.
27. le Maire A, et al. (2012) Retinoid receptors and therapeutic applications of RAR/RXR modulators. Curr Top Med Chem 12(6):505-527.
28. Perez E, Bourguet W, Gronemeyer H, de Lera AR (2012) Modulation of RXR function through ligand design. Biochim Biophys Acta 1821(1):57-69.
29. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H (2007) RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 6(10):793-810.
30. Ghose AK, Crippen GM(1986) Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships. I. Partition coefficients as a measure of hydrophobicity. J Comput Chem 7(4):565-577.
31. Leach AR (2001) Molecular Modelling: Principles and Applications (Pearson Education, Essex, UK).
32. Padayachee ER, et al. (2016) Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE e4 allele. Brain Res 1651:11-16.
33. Hellstrand E, Boland B, Walsh DM, Linse S (2010) Amyloid β-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process. ACS Chem Neurosci 1(1):13-18.
34. Arosio P, Cukalevski R, Frohm B, Knowles TP, Linse S (2014) Quantification of the concentration of Aβ42 propagons during the lag phase by an amyloid chain reaction assay. J Am Chem Soc 136(1):219-225.
35. Delaglio F, et al. (1995) NMRPipe: A multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 6(3):277-293.
36. Tetko IV, et al. (2005) Virtual computational chemistry laboratory-design and description. J Comput Aided Mol Des 19(6):453-463.
37. McColl G, et al. (2012) Utility of an improved model of amyloid-beta (Aβ1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease. Mol Neurodegener 7:57.
38. Brenner S (1974) The genetics of Caenorhabditis elegans. Genetics 77(1):71-94.
39. Solis GM, Petrascheck M (2011) Measuring Caenorhabditis elegans life span in 96 well microtiter plates. J Vis Exp 49:2496.